Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Published byAlbert Chandler Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue."— Presentation transcript:

1 Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue or reduction in motivation is experienced) (n=157). From: Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy Ann Oncol. 2005;16(3): doi: /annonc/mdi095 Ann Oncol | © 2005 European Society for Medical Oncology

2 Figure 2. The course of mental fatigue as a function of the days between the operation and the start of chemotherapy. From: Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy Ann Oncol. 2005;16(3): doi: /annonc/mdi095 Ann Oncol | © 2005 European Society for Medical Oncology

3 Figure 3. The course of mental fatigue as a function of the number of chemotherapy treatments.
From: Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy Ann Oncol. 2005;16(3): doi: /annonc/mdi095 Ann Oncol | © 2005 European Society for Medical Oncology

4 Figure 4. The course of mental fatigue and reduction in motivation for married women (n=131).
From: Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy Ann Oncol. 2005;16(3): doi: /annonc/mdi095 Ann Oncol | © 2005 European Society for Medical Oncology

Download ppt "Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue."

Similar presentations

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

The Call (a brief tour of breast cancer) Family Medicine Review Course 2011 Christian Cable, MD, FACP.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Symptom Distress During Breast Cancer Chemotherapy Does Race Matter? Margaret Quinn Rosenzweig, PhD, FNP-BC,AOCNP Associate Professor University of Pittsburgh.

Symptom Distress During Breast Cancer Chemotherapy Does Race Matter? Margaret Quinn Rosenzweig, PhD, FNP-BC,AOCNP Associate Professor University of Pittsburgh.
Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation.

Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
QOL surveys every 2 months for 2 years.

QOL surveys every 2 months for 2 years.
A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.

A. Schema of NSABP B-27 trial comparing neoadjuvant AC to neoadjuvant AC followed by neoadjuvant docetaxel and to neoadjuvant AC followed by adjuvant docetaxel.
Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;

Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;
Volume 8, Issue 12, Pages (December 2007)

Volume 8, Issue 12, Pages (December 2007)
Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure:

Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure:
Mean Responses on PGI-Improvement Primary Endpoint at Week 12

Mean Responses on PGI-Improvement Primary Endpoint at Week 12
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1 (A) Chest computed tomography scans of the patient

Figure 1 (A) Chest computed tomography scans of the patient
Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. (A) Sézary syndrome patient before treatment
Neo-adjuvant treatment for metastatic colon cancer in geriatric patients followed by simultaneous hepatic resection: A case report Sotiropoulos GC, Machairas.

Neo-adjuvant treatment for metastatic colon cancer in geriatric patients followed by simultaneous hepatic resection: A case report Sotiropoulos GC, Machairas.
Oncology for Family Medicine Residents:

Oncology for Family Medicine Residents:

Similar presentations

Ads by Google